{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:22:20Z","timestamp":1790882540924,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Spanish Health Ministry\u2019s Research Found","award":["FIS PI20\/00022"],"award-info":[{"award-number":["FIS PI20\/00022"]}]},{"name":"Spanish Health Ministry\u2019s Research Found","award":["FIS PI20\/00022"],"award-info":[{"award-number":["FIS PI20\/00022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"DOI":"10.1186\/s13054-026-06075-w","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:36:20Z","timestamp":1778668580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intrapulmonary penetration of ceftolozane\/tazobactam and ceftazidime\/avibactam administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial"],"prefix":"10.1186","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4794-5936","authenticated-orcid":false,"given":"Adela","family":"Ben\u00edtez-Cano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymara","family":"Sancho-Araiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Carazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"S\u00e1nchez-Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Chalela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"L\u00f3pez-Palacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco F.","family":"Garc\u00eda-Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Eugenia","family":"Navarrete-Rouco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Juanes-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"G\u00f3mez-Junyent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Horcajada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Adalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Sorl\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"6075_CR1","doi-asserted-by":"publisher","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"A Torres","year":"2017","unstructured":"Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, Kollef M, Li Bassi G, Luna CM, Martin-Loeches I, Paiva JA, Read RC, Rigau D, Timsit JF, Welte T, Wunderink R. International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT). Eur Respir J. 2017;50:1700582.","journal-title":"Eur Respir J"},{"key":"6075_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","volume":"63","author":"D van Duin","year":"2016","unstructured":"van Duin D, Bonomo RA. Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: Second-generation \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combinations. Clin Infect Dis. 2016;63:234\u201341.","journal-title":"Clin Infect Dis"},{"key":"6075_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","volume":"18","author":"A Torres","year":"2018","unstructured":"Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, Song J, Taylor D, Laud PJ, Stone GG, Chow JW. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285\u201395.","journal-title":"Lancet Infect Dis"},{"key":"6075_CR4","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","volume":"19","author":"MH Kollef","year":"2019","unstructured":"Kollef MH, Nov\u00e1\u010dek M, Kivistik \u00dc, R\u00e9a-Neto \u00c1, Shime N, Martin-Loeches I, Timsit JF, Wunderink RG, Bruno CJ, Huntington JA, Lin G, Yu B, Butterton JR, Rhee EG. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19:1299\u2013311.","journal-title":"Lancet Infect Dis"},{"key":"6075_CR5","doi-asserted-by":"publisher","first-page":"e01117","DOI":"10.1128\/AAC.01117-17","volume":"61","author":"PA Fraile-Ribot","year":"2017","unstructured":"Fraile-Ribot PA, Mulet X, Cabot G, Del Barrio-Tofi\u00f1o E, Juan C, P\u00e9rez JL, Oliver A. Vivo Emergence of Resistance to Novel Cephalosporin-\u03b2-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 \u03b2-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61:e01117\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"6075_CR6","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1093\/jac\/dkz330","volume":"74","author":"S G\u00f6ttig","year":"2019","unstructured":"G\u00f6ttig S, Frank D, Mungo E, Nolte A, Hogardt M, Besier S, Wichelhaus TA. Emergence of ceftazidime\/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo. J Antimicrob Chemother. 2019;74:3211\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"6075_CR7","doi-asserted-by":"crossref","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, Neely MN, Paiva JA, Pea F, Sjovall F, Timsit JF, Udy AA, Wicha SG, Zeitlinger M, De Waele JJ, Roberts JA, Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic\/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and, Diseases I (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and, Toxicology C. (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020;46:1127-53.","DOI":"10.1007\/s00134-020-06050-1"},{"key":"6075_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cmi.2025.11.009","volume":"32","author":"M Rinaldi","year":"2026","unstructured":"Rinaldi M, Gatti M, Giannella M. Avoiding resistance development to newer drugs: open research lines. Clin Microbiol Infect. 2026;32:543\u201353.","journal-title":"Clin Microbiol Infect"},{"key":"6075_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13054-024-04911-5","volume":"28","author":"M Gatti","year":"2024","unstructured":"Gatti M, Cojutti PG, Pea F. Impact of attaining aggressive vs. conservative PK\/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis. Crit Care. 2024;28:123.","journal-title":"Crit Care"},{"issue":"8","key":"6075_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jama.2024.9779","volume":"332","author":"JM Dulhunty","year":"2024","unstructured":"Dulhunty JM, Brett SJ, De Waele JJ, Rajbhandari D, Billot L, Cotta MO, Davis JS, Finfer S, Hammond NE, Knowles S, Liu X, McGuinness S, Mysore J, Paterson DL, Peake S, Rhodes A, Roberts JA, Roger C, Shirwadkar C, Starr T, Taylor C, Myburgh JA, Lipman J. BLING III Study Investigators. Continuous vs Intermittent \u03b2-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. JAMA. 2024;332(8):629\u201337.","journal-title":"JAMA"},{"key":"6075_CR11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1001\/jama.2024.9803","volume":"332","author":"MH Abdul-Aziz","year":"2024","unstructured":"Abdul-Aziz MH, Hammond NE, Brett SJ, Cotta MO, De Waele JJ, Devaux A, Di Tanna GL, Dulhunty JM, Elkady H, Eriksson L, Hasan MS, Khan AB, Lipman J, Liu X, Monti G, Myburgh J, Novy E, Omar S, Rajbhandari D, Roger C, Sj\u00f6vall F, Zaghi I, Zangrillo A, Delaney A, Roberts JA. Prolonged vs Intermittent Infusions of \u03b2-Lactam Antibiotics in Adults With Sepsis or Septic Shock: A Systematic Review and Meta-Analysis. JAMA. 2024;332:638\u201348.","journal-title":"JAMA"},{"key":"6075_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00228-019-02804-z","volume":"76","author":"S Das","year":"2020","unstructured":"Das S, Zhou D, Nichols WW, Townsend A, Newell P, Li J. Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia. Eur J Clin Pharmacol. 2020;76:349\u201361.","journal-title":"Eur J Clin Pharmacol"},{"key":"6075_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/jcph.566","volume":"56","author":"AJ Xiao","year":"2016","unstructured":"Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane\/tazobactam pharmacokinetic\/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016;56:56\u201366.","journal-title":"J Clin Pharmacol"},{"key":"6075_CR14","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S1473-3099(24)00648-0","volume":"25","author":"RK Shields","year":"2025","unstructured":"Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Burgoon R, Cifuentes R, Claeys KC, Curry BN, DeSear KE, Gallagher JC, Golnabi EY, Gross AE, Hand J, Heil EL, Hornback KM, Kaye KS, Khuu TV, Klatt ME, Kline EG, Kubat RC, Kufel WD, Lee JH, Lepak AJ, Lim A, Ludwig JM, Macdougall C, Majumdar A, Mathers AJ, McCreary EK, Miller WR, Monogue ML, Moore WJ, Olson S, Oxer J, Pearson JC, Pham C, Pinargote P, Polk C, Satlin MJ, Satola SW, Shah S, Tamma PD, Tran TT, van Duin D, VanNatta M, Vega A, Venugopalan V, Veve MP, Wangchinda W, Witt LS, Wu JY, Pogue JM. PRECEDENT Network. Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study. Lancet Infect Dis. 2025;25:574\u201384.","journal-title":"Lancet Infect Dis"},{"key":"6075_CR15","doi-asserted-by":"publisher","first-page":"ciag194","DOI":"10.1093\/cid\/ciag194","volume":"18","author":"M Gatti","year":"2026","unstructured":"Gatti M, De Paola R, Giorgi B, Pea F. Comparison of ceftolozane-tazobactam and ceftazidime-avibactam in the treatment of MDR\/DTR Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Clin Infect Dis. 2026;18:ciag194.","journal-title":"Clin Infect Dis"},{"key":"6075_CR16","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/jac\/dkaa049","volume":"75","author":"L Caro","year":"2020","unstructured":"Caro L, Nicolau DP, De Waele JJ, Kuti JL, Larson KB, Gadzicki E, Yu B, Zeng Z, Adedoyin A, Rhee EG. Lung penetration, bronchopulmonary pharmacokinetic\/pharmacodynamic profile and safety of 3\u00a0g of ceftolozane\/tazobactam administered to ventilated, critically ill patients with pneumonia. J Antimicrob Chemother. 2020;75:1546\u201353.","journal-title":"J Antimicrob Chemother"},{"key":"6075_CR17","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61\u2013111.","journal-title":"Clin Infect Dis"},{"key":"6075_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-020-2763-4","volume":"24","author":"A Ben\u00edtez-Cano","year":"2020","unstructured":"Ben\u00edtez-Cano A, Luque S, Sorl\u00ed L, Carazo J, Ramos I, Campillo N, et al. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: A randomized pharmacokinetic trial. Crit Care. 2020;24:1\u201314.","journal-title":"Crit Care"},{"key":"6075_CR19","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1345\/aph.1R721","volume":"47","author":"WJ Lam","year":"2013","unstructured":"Lam WJ, Bhowmick T, Gross A, Vanschooneveld TC, Weinstein MP. Using higher doses to compensate for tubing residuals in extended-infusion piperacillin-tazobactam. Ann Pharmacother. 2013;47:886\u201391.","journal-title":"Ann Pharmacother"},{"key":"6075_CR20","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.3390\/pharmaceutics15122705","volume":"15","author":"B Fern\u00e1ndez-Rubio","year":"2023","unstructured":"Fern\u00e1ndez-Rubio B, Herrera-Hidalgo L, de Alarc\u00f3n A, Luque-M\u00e1rquez R, L\u00f3pez-Cort\u00e9s LE, Luque S, Guti\u00e9rrez-Urb\u00f3n JM, Fern\u00e1ndez-Polo A, Guti\u00e9rrez-Valencia A, Gil-Navarro MV. Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy. Pharmaceutics. 2023;15:2705.","journal-title":"Pharmaceutics"},{"key":"6075_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"6075_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/BF00273563","volume":"15","author":"G Giangiuliani","year":"1989","unstructured":"Giangiuliani G, Mancini A, Gui D. Validation of a severity of illness score (APACHE II) in a surgical intensive care unit. Intensive Care Med. 1989;15:519\u201322.","journal-title":"Intensive Care Med"},{"key":"6075_CR23","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendon\u00e7a A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707\u201310.","journal-title":"Intensive Care Med"},{"key":"6075_CR24","unstructured":"Clinical Breakpoints-Bacteria. http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 20 Feb. 2026."},{"key":"6075_CR25","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1164\/rccm.201202-0320ST","volume":"185","author":"KC Meyer","year":"2012","unstructured":"Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, Drent M, Haslam PL, Kim DS, Nagai S, Rottoli P, Saltini C, Selman M, Strange C, Wood B, American Thoracic Society Committee on BAL in Interstitial Lung Disease. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185:1004\u201314.","journal-title":"Am J Respir Crit Care Med"},{"key":"6075_CR26","unstructured":"ZERBAXA\u00ae. feb. (Ceftolozane and Tazobactam) for Injection, for intravenous use. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zerbaxa\/zerbaxa_pi.pdf. Accessed 13 2026."},{"key":"6075_CR27","unstructured":"ZAVICEFTA\u00ae. feb. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=15402. Accessed 13 2026."},{"key":"6075_CR28","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1164\/ajrccm.160.3.9811049","volume":"160","author":"PA Dargaville","year":"1999","unstructured":"Dargaville PA, South M, Vervaart P, McDougall PN. Validity of markers of dilution in small volume lung lavage. Am J Respir Crit Care Med. 1999;160:778\u201384.","journal-title":"Am J Respir Crit Care Med"},{"key":"6075_CR29","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1164\/rccm.200301-111OC","volume":"168","author":"K Yamazaki","year":"2003","unstructured":"Yamazaki K, Ogura S, Ishizaka A, Oh-hara T, Nishimura M. Bronchoscopic microsampling method for measuring drug concentration in epithelial lining fluid. Am J Respir Crit Care Med. 2003;168:1304\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"6075_CR30","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2:e38.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"6075_CR31","unstructured":"Clinical Breakpoints-Bacteria. https:\/\/www.eucast.org\/fileadmin\/eucast\/pdf\/breakpoints\/v_16.0_Breakpoint_Tables.pdf. Accessed 13 Feb. 2026."},{"key":"6075_CR32","doi-asserted-by":"publisher","first-page":"w14368","DOI":"10.4414\/smw.2016.14368","volume":"146","author":"M Osthoff","year":"2016","unstructured":"Osthoff M, Siegemund M, Balestra G, Abdul-Aziz MH, Roberts JA. Prolonged administration of \u03b2-lactam antibiotics - a comprehensive review and critical appraisal. Swiss Med Wkly. 2016;146:w14368.","journal-title":"Swiss Med Wkly"},{"key":"6075_CR33","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2165\/11592900-000000000-00000","volume":"50","author":"KA Rodvold","year":"2011","unstructured":"Rodvold KA, Yoo L, George JM. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents. Clin Pharmacokinet. 2011;50:689\u2013704.","journal-title":"Clin Pharmacokinet"},{"key":"6075_CR34","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3390\/antibiotics11121839","volume":"11","author":"JG Pereira","year":"2022","unstructured":"Pereira JG, Fernandes J, Duarte AR, Fernandes SM. \u03b2-Lactam Dosing in Critical Patients: A Narrative Review of Optimal Efficacy and the Prevention of Resistance and Toxicity. Antibiot (Basel). 2022;11:1839.","journal-title":"Antibiot (Basel)"},{"key":"6075_CR35","doi-asserted-by":"publisher","first-page":"e0048825","DOI":"10.1128\/aac.00488-25","volume":"69","author":"M Gatti","year":"2025","unstructured":"Gatti M, Rinaldi M, Cojutti PG, Bonazzetti C, Siniscalchi A, Tonetti T, Ambretti S, Tedeschi S, Giannella M, Viale P, Pea F. A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic\/pharmacodynamic target with ceftazidime\/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on ceftazidime\/avibactam resistance development. Antimicrob Agents Chemother. 2025;69:e0048825.","journal-title":"Antimicrob Agents Chemother"},{"key":"6075_CR36","doi-asserted-by":"publisher","first-page":"e0104225","DOI":"10.1128\/aac.01042-25","volume":"69","author":"PG Cojutti","year":"2025","unstructured":"Cojutti PG, Pai MP, Gatti M, Rinaldi M, Tonetti T, Siniscalchi A, Viale P, Pea F. Targeting Pseudomonas aeruginosa resistance at the exposure frontier: a population PK\/PD blueprint for ceftolozane\/tazobactam continuous infusion. Antimicrob Agents Chemother. 2025;69:e0104225.","journal-title":"Antimicrob Agents Chemother"},{"key":"6075_CR37","doi-asserted-by":"publisher","first-page":"e0121525","DOI":"10.1128\/aac.01215-25","volume":"69","author":"MP Pai","year":"2025","unstructured":"Pai MP, Cojutti PG, Gatti M, Rinaldi M, Tonetti T, Siniscalchi A, Viale P, Pea F. Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane\/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales? Antimicrob Agents Chemother. 2025;69:e0121525.","journal-title":"Antimicrob Agents Chemother"},{"key":"6075_CR38","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1093\/jac\/dkae290","volume":"79","author":"PG Cojutti","year":"2024","unstructured":"Cojutti PG, Pai MP, Gatti M, Rinaldi M, Ambretti S, Viale P, Pea F. An innovative population pharmacokinetic\/pharmacodynamic strategy for attaining aggressive joint PK\/PD target of continuous infusion ceftazidime\/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients. J Antimicrob Chemother. 2024;79:2801\u201308.","journal-title":"J Antimicrob Chemother"},{"key":"6075_CR39","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s15010-023-02167-9","volume":"52","author":"D Vanneste","year":"2024","unstructured":"Vanneste D, Gijsen M, Maertens J, Van Paesschen W, Debaveye Y, Wauters J, Spriet I. Ceftazidime-related neurotoxicity in a patient with renal impairment: a case report and literature review. Infection. 2024;52:1113\u201323.","journal-title":"Infection"},{"key":"6075_CR40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jns.2019.01.018","volume":"398","author":"C Lacroix","year":"2019","unstructured":"Lacroix C, Kheloufi F, Montastruc F, Bennis Y, Pizzoglio V, Micallef J. Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database. J Neurol Sci. 2019;398:196\u2013201.","journal-title":"J Neurol Sci"},{"key":"6075_CR41","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1128\/AAC.01580-16","volume":"60","author":"MJ Melchers","year":"2016","unstructured":"Melchers MJ, Mavridou E, van Mil AC, Lagarde C, Mouton JW. Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model. Antimicrob Agents Chemother. 2016;60:7272\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"6075_CR42","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1128\/AAC.01269-15","volume":"60","author":"J Berkhout","year":"2015","unstructured":"Berkhout J, Melchers MJ, van Mil AC, Seyedmousavi S, Lagarde CM, Schuck VJ, Nichols WW, Mouton JW. Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. Antimicrob Agents Chemother. 2015;60:368\u201375.","journal-title":"Antimicrob Agents Chemother"},{"key":"6075_CR43","doi-asserted-by":"publisher","first-page":"e0096923","DOI":"10.1128\/aac.00969-23","volume":"67","author":"M Gatti","year":"2023","unstructured":"Gatti M, Rinaldi M, Bonazzetti C, Gaibani P, Giannella M, Viale P, Pea F. Could an optimized joint pharmacokinetic\/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections? Antimicrob Agents Chemother. 2023;67:e0096923.","journal-title":"Antimicrob Agents Chemother"},{"key":"6075_CR44","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.coph.2017.09.019","volume":"36","author":"KA Rodvold","year":"2017","unstructured":"Rodvold KA, Hope WW, Boyd SE. Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung. Curr Opin Pharmacol. 2017;36:114\u201323.","journal-title":"Curr Opin Pharmacol"},{"key":"6075_CR45","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0924-8579(02)00024-9","volume":"19","author":"P Liu","year":"2002","unstructured":"Liu P, M\u00fcller M, Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents. 2002;19:285\u201390.","journal-title":"Int J Antimicrob Agents"},{"key":"6075_CR46","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1128\/AAC.04627-14","volume":"59","author":"J Berkhout","year":"2015","unstructured":"Berkhout J, Melchers MJ, van Mil AC, Seyedmousavi S, Lagarde CM, Nichols WW, Mouton JW. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother. 2015;59:2299\u2013304.","journal-title":"Antimicrob Agents Chemother"},{"key":"6075_CR47","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1093\/jac\/dkv170","volume":"70","author":"DP Nicolau","year":"2015","unstructured":"Nicolau DP, Siew L, Armstrong J, Li J, Edeki T, Learoyd M, Das S. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J Antimicrob Chemother. 2015;70:2862\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"6075_CR48","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00134-004-2171-2","volume":"30","author":"E Boselli","year":"2004","unstructured":"Boselli E, Breilh D, Rimmel\u00e9 T, Poupelin JC, Saux MC, Chassard D, Allaouchiche B. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 2004;30:989\u201391.","journal-title":"Intensive Care Med"},{"key":"6075_CR49","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s13318-022-00772-x","volume":"47","author":"ME Navarrete-Rouco","year":"2022","unstructured":"Navarrete-Rouco ME, Luque S, Sorl\u00ed L, Ben\u00edtez-Cano A, Roberts JA, Grau S. Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane\/Tazobactam for MDR\/XDR Pseudomonas aeruginosa Infections: An Observational Study. Eur J Drug Metab Pharmacokinet. 2022;47:561\u20136.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"6075_CR50","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/jac\/dkac439","volume":"78","author":"D Fresan","year":"2023","unstructured":"Fresan D, Luque S, Ben\u00edtez-Cano A, Sorl\u00ed L, Milagro Montero M, De-Antonio M, Prim N, Vega V, Horcajada JP, Grau S. Pharmacokinetics\/pharmacodynamics and therapeutic drug monitoring of ceftazidime\/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections. J Antimicrob Chemother. 2023;78:678\u201383.","journal-title":"J Antimicrob Chemother"},{"key":"6075_CR51","doi-asserted-by":"publisher","first-page":"e00124","DOI":"10.1128\/AAC.00124-21","volume":"65","author":"GL Drusano","year":"2021","unstructured":"Drusano GL, Bonomo RA, Marshall SM, Rojas LJ, Adams MD, Mojica MF, Kreiswirth BN, Chen L, Mtchedlidze N, Bacci M, Vicchiarelli M, Bulitta JB, Louie A. Emergence of Resistance to Ceftazidime-Avibactam in a Pseudomonas aeruginosa Isolate Producing Derepressed blaPDC in a Hollow-Fiber Infection Model. Antimicrob Agents Chemother. 2021;65:e00124\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"6075_CR52","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1128\/AAC.00727-15","volume":"60","author":"AP MacGowan","year":"2015","unstructured":"MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection. Antimicrob Agents Chemother. 2015;60:515\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"6075_CR53","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3390\/microorganisms9071505","volume":"9","author":"C Roger","year":"2021","unstructured":"Roger C, Louart B. Beta-Lactams Toxicity in the Intensive Care Unit: An Underestimated Collateral Damage? Microorganisms. 2021;9:1505.","journal-title":"Microorganisms"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-026-06075-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-06075-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-06075-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:06:08Z","timestamp":1781186768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13054-026-06075-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6075"],"URL":"https:\/\/doi.org\/10.1186\/s13054-026-06075-w","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the local ethics committee (Comit\u00e8 Etic. d\u2019Investigaci\u00f3 Cl\u00ednica del Parc de Salut Mar; approval no. 2021\/10203). Written informed consent was obtained either from the patient or their appointed legal guardian.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"305"}}